SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort.
Identifying the potential for SARS-CoV-2 reinfection is crucial for understanding possible long-term epidemic dynamics. We analysed longitudinal PCR and serological testing data from a prospective cohort of 4,411 United States employees in 4 states between April 2020 and February 2021. We conducted...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-02-01
|
| Series: | PLoS Biology |
| Online Access: | https://journals.plos.org/plosbiology/article/file?id=10.1371/journal.pbio.3001531&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850160495336620032 |
|---|---|
| author | Emilie Finch Rachel Lowe Stephanie Fischinger Michael de St Aubin Sameed M Siddiqui Diana Dayal Michael A Loesche Justin Rhee Samuel Beger Yiyuan Hu Matthew J Gluck Benjamin Mormann Mohammad A Hasdianda Elon R Musk Galit Alter Anil S Menon Eric J Nilles Adam J Kucharski CMMID COVID-19 working group and the SpaceX COVID-19 Cohort Collaborative |
| author_facet | Emilie Finch Rachel Lowe Stephanie Fischinger Michael de St Aubin Sameed M Siddiqui Diana Dayal Michael A Loesche Justin Rhee Samuel Beger Yiyuan Hu Matthew J Gluck Benjamin Mormann Mohammad A Hasdianda Elon R Musk Galit Alter Anil S Menon Eric J Nilles Adam J Kucharski CMMID COVID-19 working group and the SpaceX COVID-19 Cohort Collaborative |
| author_sort | Emilie Finch |
| collection | DOAJ |
| description | Identifying the potential for SARS-CoV-2 reinfection is crucial for understanding possible long-term epidemic dynamics. We analysed longitudinal PCR and serological testing data from a prospective cohort of 4,411 United States employees in 4 states between April 2020 and February 2021. We conducted a multivariable logistic regression investigating the association between baseline serological status and subsequent PCR test result in order to calculate an odds ratio for reinfection. We estimated an odds ratio for reinfection ranging from 0.14 (95% CI: 0.019 to 0.63) to 0.28 (95% CI: 0.05 to 1.1), implying that the presence of SARS-CoV-2 antibodies at baseline is associated with around 72% to 86% reduced odds of a subsequent PCR positive test based on our point estimates. This suggests that primary infection with SARS-CoV-2 provides protection against reinfection in the majority of individuals, at least over a 6-month time period. We also highlight 2 major sources of bias and uncertainty to be considered when estimating the relative risk of reinfection, confounders and the choice of baseline time point, and show how to account for both in reinfection analysis. |
| format | Article |
| id | doaj-art-9bee598a3b3d4b53a4f599012d679ba0 |
| institution | OA Journals |
| issn | 1544-9173 1545-7885 |
| language | English |
| publishDate | 2022-02-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Biology |
| spelling | doaj-art-9bee598a3b3d4b53a4f599012d679ba02025-08-20T02:23:08ZengPublic Library of Science (PLoS)PLoS Biology1544-91731545-78852022-02-01202e300153110.1371/journal.pbio.3001531SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort.Emilie FinchRachel LoweStephanie FischingerMichael de St AubinSameed M SiddiquiDiana DayalMichael A LoescheJustin RheeSamuel BegerYiyuan HuMatthew J GluckBenjamin MormannMohammad A HasdiandaElon R MuskGalit AlterAnil S MenonEric J NillesAdam J KucharskiCMMID COVID-19 working group and the SpaceX COVID-19 Cohort CollaborativeIdentifying the potential for SARS-CoV-2 reinfection is crucial for understanding possible long-term epidemic dynamics. We analysed longitudinal PCR and serological testing data from a prospective cohort of 4,411 United States employees in 4 states between April 2020 and February 2021. We conducted a multivariable logistic regression investigating the association between baseline serological status and subsequent PCR test result in order to calculate an odds ratio for reinfection. We estimated an odds ratio for reinfection ranging from 0.14 (95% CI: 0.019 to 0.63) to 0.28 (95% CI: 0.05 to 1.1), implying that the presence of SARS-CoV-2 antibodies at baseline is associated with around 72% to 86% reduced odds of a subsequent PCR positive test based on our point estimates. This suggests that primary infection with SARS-CoV-2 provides protection against reinfection in the majority of individuals, at least over a 6-month time period. We also highlight 2 major sources of bias and uncertainty to be considered when estimating the relative risk of reinfection, confounders and the choice of baseline time point, and show how to account for both in reinfection analysis.https://journals.plos.org/plosbiology/article/file?id=10.1371/journal.pbio.3001531&type=printable |
| spellingShingle | Emilie Finch Rachel Lowe Stephanie Fischinger Michael de St Aubin Sameed M Siddiqui Diana Dayal Michael A Loesche Justin Rhee Samuel Beger Yiyuan Hu Matthew J Gluck Benjamin Mormann Mohammad A Hasdianda Elon R Musk Galit Alter Anil S Menon Eric J Nilles Adam J Kucharski CMMID COVID-19 working group and the SpaceX COVID-19 Cohort Collaborative SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort. PLoS Biology |
| title | SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort. |
| title_full | SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort. |
| title_fullStr | SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort. |
| title_full_unstemmed | SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort. |
| title_short | SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort. |
| title_sort | sars cov 2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort |
| url | https://journals.plos.org/plosbiology/article/file?id=10.1371/journal.pbio.3001531&type=printable |
| work_keys_str_mv | AT emiliefinch sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort AT rachellowe sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort AT stephaniefischinger sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort AT michaeldestaubin sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort AT sameedmsiddiqui sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort AT dianadayal sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort AT michaelaloesche sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort AT justinrhee sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort AT samuelbeger sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort AT yiyuanhu sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort AT matthewjgluck sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort AT benjaminmormann sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort AT mohammadahasdianda sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort AT elonrmusk sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort AT galitalter sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort AT anilsmenon sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort AT ericjnilles sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort AT adamjkucharski sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort AT cmmidcovid19workinggroupandthespacexcovid19cohortcollaborative sarscov2antibodiesprotectagainstreinfectionforatleast6monthsinamulticentreseroepidemiologicalworkplacecohort |